GoodRx to Restate First-Half 2026 Financials Over Understated Revenue

• GoodRx Holdings on October 27, 2026, deemed first- and second-quarter financial statements unreliable due to understated Pharma Direct revenue.
• Revenue recognition errors violated ASC 606 requirements; amended Forms 10-Q will restate the affected periods.
• Expected adjustments would raise first-half total revenue by $29.77 million to $424.19 million.
• First-half net income is expected to increase by $14.85 million to $24.55 million.
• One or more material weaknesses in internal control over financial reporting are expected for both affected quarters.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GoodRx Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001809519-26-000184), on November 02, 2026, and is solely responsible for the information contained therein.